Skip to content

A study on the treatment of dry eye diseaseby Zhangyanming tablets

A randomized, double-blind, controlled study on the treatment of dry eye disease (Gan Shen Yin Xu Pattern ) by Zhangyanming tablets

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061479
Enrollment
Unknown
Registered
2022-06-26
Start date
2022-06-13
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Xerophthalmia

Interventions

Experimental group:Sodium hyaluronate eye drops (0.1%), 1 drop, 5 times a day. Oral Zhangyanming tablets, 2 tablets each time, 3 times a day.
Control group:Sodium hyaluronate eye drops (0.1%), 1 drop, 5 times a day. Oral Zhangyanming placebo tablets, 2 tablets each time, 3 times a day.

Sponsors

Zhongshan Ophthalmic Center Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Agree to participate in the clinical trial and sign the informed consent form; 2. Meet the diagnostic criteria of xerophthalmia; 3. Meet the diagnostic criteria of TCM of GanShenyinxu syndrome; 4. Aged 40-75 years, no gender limit; 5. Simple dry eye disease; 6. Before entering the group, no other drug treatment was used, or other drug treatment was used, but the drug was stopped for more than 2 weeks; 7. Binocular corrected visual acuity >= 0.2.

Exclusion criteria

Exclusion criteria: 1. Known or suspected allergic history or severe adverse reaction to the test drug and its excipients, or allergic constitution. 2. Systemic diseases, diabetes, glaucoma. 3. Complicated with severe liver and kidney disease, or abnormal liver and kidney function (ALT and AST >= 1.5 times the upper limit of normal, SCr > the upper limit of normal). 4. Unable to cooperate or unwilling to cooperate because of neurological or mental illness. 5. Suspected or confirmed history of alcohol and drug abuse. 6. Pregnant or lactating patients or those who have recently planned to give birth. 7. Patients in other situations considered unsuitable by the researchers for this study. 8. Patients who had participated in other clinical trials within 1 month before inclusion.

Design outcomes

Primary

MeasureTime frame
tear film break time (BUT);Schirmer ? test;Ocular Surface Disease Index;

Secondary

MeasureTime frame
fluorescein staining of cornea and conjunctiva;TCM syndrome score;

Countries

China

Contacts

Public ContactGu Jianjun
15622271658@163.com+86 13434313986

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 14, 2026